Amgen Stock Rises Despite 55.91% Volume Drop to 110th Ranking

On June 2, 2025, Amgen's trading volume reached $689 million, a significant 55.91% decrease from the previous day, placing it at the 110th position in the day's stock market rankings. Amgen's stock price increased by 0.10%, marking its third consecutive day of gains, with a total increase of 3.62% over the past three days.

Amgen's immunotherapy drug, Imdelltra, has shown promising results in reducing the risk of death by 40% for small cell lung cancer patients whose disease had progressed after initial treatment. This breakthrough second-line treatment demonstrated a significant survival advantage, extending overall survival by more than five months compared to standard chemotherapy.

The positive interim results from the Phase 3 DeLLphi-304 study further solidified Imdelltra's potential. The trial not only confirmed the 40% reduction in mortality risk but also highlighted the drug's safety profile, which remained consistent with previous findings. This consistency boosts confidence in Imdelltra's market impact and its potential to become a key player in lung cancer treatment.

Analysts have responded positively to these developments, forecasting a potential upside for Amgen's stock. The strong performance metrics and the drug's significant benefits have led to optimistic market perspectives, with analysts emphasizing the stock's potential for growth.